Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 9 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

9Total
Not Applicable (1)
P 1 (6)
P 2 (2)

Trial Status

Not Yet Recruiting5
Recruiting3
Active Not Recruiting1

Clinical Trials (9)

Showing 9 of 9 trials
NCT07738939Phase 1Not Yet Recruiting

IKS04 Regimen in Advanced Solid Tumors That Express CA242

NCT07670312Phase 1Not Yet Recruiting

Evaluation of XYA02 in Patients With Advanced Solid Tumors

NCT07454642Phase 1Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07493382Not ApplicableNot Yet RecruitingPrimary

Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy

NCT04430738Phase 2Active Not Recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT07182149Phase 1Recruiting

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07334431Phase 1Recruiting

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

NCT06888037Phase 2Not Yet Recruiting

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

NCT06871527Phase 1Not Yet Recruiting

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Showing all 9 trials

Research Network

Activity Timeline